110 results about "Edaravone" patented technology

The invention provides a medicine for preventing and treating cerebral arterial thrombosis, and belongs to the technical field of neuromedicine. The medicine comprises salmon polypeptide as shown in SEQ ID NO.1 and a pharmaceutically acceptable carrier, and experimental results show that the salmon polypeptide has good safety, can effectively improve oxygen-glucose deprivation / reoxygenation injury of brain cells, and remarkably reduces neurological impairment and cerebral infarction of mice suffering from cerebral arterial thrombosis. The invention also discloses a pharmaceutical composition for treating cerebral arterial thrombosis. The pharmaceutical composition comprises the salmon polypeptide and edaravone. The composition shows a remarkable synergistic effect, compared with the single use of the salmon polypeptide or edaravone, the composition can more remarkably reduce neurological impairment and cerebral infarction, and the actual effect is obviously superior to the theoretical superposition effect. Therefore, the invention provides a novel and more effective treatment scheme for the treatment of cerebral arterial thrombosis.

The present application belongs to the field of medical technology, and in particular, relates to an edaravone dexamethasone solution and its preparation process and application. The preparation process of the edaravone dexamethasone solution comprises the steps of: dissolving edaravone in a heated organic solvent under an inert atmosphere, cooling to no more than 30°C, adding dexamethasone to dissolve, and obtaining a mixed solution; adding water and an antioxidant to the mixed solution under an inert atmosphere for mixing treatment, adjusting the pH value of the solution to 4 to 4.5, and obtaining an edaravone dexamethasone solution. The order and conditions of adding each raw material component in the preparation process of the edaravone dexamethasone solution of the present application improve the solubility of edaravone and dexamethasone in water, solve the problem that edaravone is easily oxidized and dexamethasone is easily volatilized at room temperature, have low impurity content, good pH stability, high product quality and stability, and are conducive to the long-term preservation of the edaravone dexamethasone solution.

A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Edaravone or a pharmaceutically acceptable salt thereof is disclosed for use in the treatment of an oxidative stress-mediated neurodegenerative disorder, wherein the treatment comprises orally or gastrically administering any of them to human subjects in need thereof once daily in the morning, at a daily dose ranging from 80 to 120 mg, during an uninterrupted period of at least 1 month, wherein the human subjects have fasted for at least 2 hours before administration.

The invention provides a preparation method of an edaravone and dextroborneol injection, the injection comprises edaravone, dextroborneol, propylene glycol and sodium pyrosulfite, in the preparation process, the propylene glycol accounting for 60%-85% of the prescription dosage and water accounting for 5%-25% of the prescription dosage are injected into a liquid preparation tank according to the volume ratio, the mixture is heated to 50-60 DEG C, edaravone is added and stirred to be dissolved, and the edaravone and dextroborneol injection is prepared. The preparation method comprises the following steps: dissolving propylene glycol in the remaining prescription dosage, adding dextroborneol which is dissolved by propylene glycol in the remaining prescription dosage in advance, uniformly stirring, adding water which is close to a constant volume, cooling to 25 DEG C or below, adding sodium pyrosulfite, adjusting the pH value to 4.0-5.0, and fixing the volume to a full volume. According to the preparation method of the edaravone dextroborneol injection, auxiliary materials in a specific proportion are matched with the preparation steps, the problem that raw material medicines are extremely easy to separate out in the preparation process is solved, the requirement of the preparation process for an industrial liquid preparation tank is low, industrial operation is convenient, and the preparation cost is low.

The invention provides application of edaravone and pharmaceutically acceptable salts thereof in prevention and / or treatment of acute high altitude diseases caused by acute plateau hypobaric hypoxia. The acute high altitude diseases include, for example, acute altitude stress (AMS), plateau acute brain injury (HACE), and plateau acute lung injury (HAPE). In addition, the present disclosure provides the use of edaravone and pharmaceutically acceptable salts thereof for the prevention and / or treatment of inflammatory responses caused by plateau pulmonary arterial hypertension (HAPH) and acute plateau hypobaric hypoxia.

The invention provides a production process of an acute ischemic stroke neuroprotective agent, and particularly relates to a method for preparing an edaravone dextroborneol concentrated solution for injection, and the method comprises the following steps: adding a liquid medicine containing propylene glycol, edaravone, dextroborneol and sodium pyrosulfite into a liquid preparation tank; the temperature of the liquid medicine is controlled to be 0-50 DEG C, the pH value of the liquid medicine is adjusted to be 3.0-7.0, the liquid medicine is conveyed into an ampoule bottle through a conveying pipeline, the conveying pipeline is a pipe, and the ampoule bottle is filled with the liquid medicine through the pipe through a pump. According to the preparation method, the loss of effective components in the production and storage process of the liquid medicine is greatly reduced, the stability of the liquid medicine can be remarkably improved, and the preparation process is good in consistency, repeatable and suitable for industrial production.

The present invention relates to liquid pharmaceutical compositions of edaravone. More specifically, stable solutions of edaravone for enteral administration are provided, wherein the composition is stable for extended period of time. The present invention further relates to stable solutions of edaravone, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by edaravone.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition for treating metabolic diseases, a preparation method and application, and the pharmaceutical composition comprises edaravone or pharmaceutically acceptable salts thereof and dextroborneol. The weight ratio of the edaravone to the dextroborneol is (10: 1)-(1: 1). The invention finds that the combination of edaravone and dextroborneol shows remarkable curative effects in the aspects of improving cognitive function, reducing blood fat, relieving fatty liver and recovering cardiac function and / or overall metabolic homeostasis; meanwhile, the pharmaceutical composition disclosed by the invention has a remarkable comprehensive treatment effect on metabolic diseases or complications (such as metabolic syndrome) of the metabolic diseases and / or vascular cognitive impairment complicated with the metabolic syndrome.

An edaravone suspension for human oral administration includes edaravone particles. a dispersant, and water.

The invention relates to an application of edaravone in prevention and treatment of cognitive impairment caused by plateau hypoxia environment, in particular to an application of edaravone or pharmaceutically acceptable salts or analogues or derivatives thereof in preparation of drugs for prevention and / or treatment of cognitive impairment caused by plateau hypobaric hypoxia. The invention surprisingly discovers that edaravone has a very good prevention and treatment effect on cognitive impairment caused by plateau hypobaric hypoxia, and particularly has an outstanding treatment effect on cognitive impairment caused by chronic plateau hypobaric hypoxia; biochemical indexes, hippocampal neurological defects, neuroinflammation and the like caused by chronic plateau hypobaric hypoxia can be improved.

The application discloses a kind of pharmaceutical composition, organ preservation fluid and its application, the pharmaceutical composition includes seduxian and edaravone.The mass ratio of seduxian and edaravone is 1:0.0001-10000.The cell protection effect of the pharmaceutical composition of the application is good, seduxian and edaravone show synergistic effect, help to obtain excellent curative effect, and reduce drug dosage, help to improve clinical drug safety.

A pharmaceutical composition, an organ preservation solution, and their applications are disclosed, wherein the pharmaceutical composition comprises cedutinib and edaravone. The mass ratio of cedutinib to edaravone is 1:0.0001-10000. The pharmaceutical composition of the present invention exhibits good cell protection effects, and cedutinib and edaravone demonstrate a synergistic effect, contributing to excellent therapeutic efficacy, reducing drug dosage, and improving clinical drug safety.

The invention relates to the technical field of pharmaceutical preparations, in particular to a concentrated solution for injection of edaravone dextroborneol and a preparation method of the concentrated solution. According to the invention, the sulfonic acid antioxidant and the amino acid antioxidant are compounded and added into the edaravone dextroborneol injection solution, so that a synergistic effect is generated on inhibition of compound oxidative degradation of edaravone dextroborneol, and the prepared edaravone dextroborneol injection concentrated solution has high stability in accelerated and long-term stability tests; related substances grow slowly, the content of main components is not obviously reduced, the appearance of the solution is almost unchanged, and the validity period of the product is obviously prolonged. The preparation method provided by the invention is stable in process and easy for industrial production, and ensures the consistency of batch-to-batch quality through the combination of nitrogen charging protection and a specific antioxidant system.

The invention belongs to the technical field of biological medicines, and particularly discloses a self-assembled nano preparation coated with a macrophage membrane as well as a preparation method and application of the self-assembled nano preparation. According to the nano preparation, nano particles formed by self-assembly of epigallocatechin gallate (EGCG), ferric chloride (FeCl3) and edaravone (EDV) serve as a core, and the outer layer of the nano preparation is coated with a macrophage membrane. The preparation method is a one-pot method and comprises the following steps: mixing and self-assembling EGCG, FeCl3 and EDV in a phosphate buffer solution, carrying out centrifugal purification, and carrying out ultrasonic fusion with a macrophage membrane. The nano preparation is uniform in particle size, has excellent free radical scavenging capacity and antioxidant activity, can effectively pass through a blood-brain barrier and target a cerebral ischemia reperfusion injury area, and shows a remarkable effect in preparation of drugs for treating cerebral arterial thrombosis.

Provided is an edaravone suspension for oral administration that can reduce the burden on ALS patients and caregivers and exhibit an ALS treatment effect equivalent to that of an injection.SOLUTION: An edaravone suspension for human oral administration including edaravone particles, a dispersant, and water is provided.SELECTED DRAWING: None

The invention relates to an edaravone-containing patch and a preparation method thereof, edaravone is used for preparing a skin local patch, and belongs to the technical field of pharmaceutical preparations, the invention provides a patch, and the patch comprises the following three parts: (1) a backing layer; (2) a drug-containing adhesive skeleton layer; and (3) a protective layer. The invention also provides a preparation method of the patch, and the preparation process comprises the following steps: dissolving the pressure-sensitive adhesive material in a proper solvent, dissolving or dispersing the medicine in the pressure-sensitive adhesive solution, then coating the mixed solution on the backing layer or the protective layer by a proper process, drying to volatilize the solvent, covering the protective layer or the backing layer, and cutting and dividing doses. The finally prepared patch is good in strength and toughness, convenient to take, simple in preparation process and rapid in effect.

The invention provides an edaravone dispersible tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, and the preparation method comprises the following steps: taking 52.5% by weight of edaravone, 0.5-5% by weight of a disintegrating agent, 0.5-5% by weight of a flow aid, 0.5-5% by weight of a sweetening agent, 0.25-5% by weight of a lubricant and the balance of a lactose microcrystalline cellulose co-treatment substance, directly and uniformly mixing, and tabletting to obtain the edaravone dispersible tablet. The lactose and microcrystalline cellulose co-treatment material integrates the advantages of lactose and cellulose, the fluidity and compressibility of total mixed powder can be guaranteed, the tablet weight difference of the tabletting process is reduced, the feasibility of mass production is guaranteed, and the production efficiency and the qualification rate of the tabletting process are improved; compared with a traditional solid dispersion process, the method has the advantages that solvent treatment, fluidized bed granulation or high-temperature drying steps are not needed, and preparation production can be completed only through direct mixing and tabletting processes, so that the influence of a humid and hot environment on the API stability is fundamentally avoided, and the product is more stable.

An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

The invention discloses an edaravone homologue as well as a method and application thereof. The edaravone homologue has a structure shown in a formula (I), in the formula (I), R1 and R2 are substituent groups at any position on a benzene ring, and R1-R2 are the same or different and are independently selected from hydrogen or C1-C3 alkyl. Compared with edaravone, the edaravone homologue disclosed by the invention has the advantages that the oxidative stress level can be more effectively reduced, neuronal apoptosis is inhibited, and cerebral ischemia reperfusion injury is improved. # imgabs0 #

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The application relates to the technical field of stem cells, and specifically discloses a drying protective agent and a cell drying process of mesenchymal stem cells. The drying protective agent provided by the application comprises the following components in the following contents: EGCG: 5-45 mg / 100 mL, hydroxytetrahydro pyrimidine: 400-520 mg / 100 mL, vitamin C: 350-500 mg / 100 mL, edaravone: 0.02-0.3 mg / 100 mL, quercitrin: 0.10-0.35 mg / 100 mL, aspartic acid: 180-280 mg / 100 mL, tetrahydro pyrimidine: 400-500 mg / 100 mL, trehalose: 10-60 g / 100 mL, dextran: 20-50 g / 100 mL, maltose: 25-40 g / 100 mL and 2,3,4,6-tetraacetyl-d-glucose: 30-60 mg / 100 mL, and the solvent is a phosphate buffer solution PBS; the application also provides a cell drying process, which comprises the following steps: cold-heat cycle treatment and drying; wherein the cold-heat cycle treatment adopts the aforementioned drying protective agent. The drying protective agent provided by the application can avoid damage of mesenchymal stem cells in the drying process, so that the survival rate of the mesenchymal stem cells after rehydration is improved.

The invention discloses solid particles of edaravone and dextroborneol prepared by a wet granulation process and a solid oral quick-release preparation prepared from the solid particles. The solid particles comprise edaravone, dextroborneol, polyethylene glycol and other pharmaceutic adjuvants. According to the present invention, the dextroborneol and the polyethylene glycol are co-dissolved in the absolute ethyl alcohol, and the wet granulation is performed with the edaravone and the pharmaceutical excipients, such that the process feasibility is significantly improved, and the particles with different particle sizes can be prepared according to the absolute ethyl alcohol use amount so as to prepare the oral quick-release tablets with different dosage forms, the dissolving-out speed of the prepared solid particle dextroborneol is obviously improved, and the stability of edaravone is also improved at the same time.

The invention discloses a lignan compound and medical application thereof.The structure of the lignan compound is shown in the formula (I), the lignan compound is derived from amomum tsao-ko and has excellent anti-oxidative stress capacity, the performance of the lignan compound is better than that of edaravone, and the lignan compound is lower in toxicity and can be used for preparing medicines for preventing and treating diseases. Therefore, the compound or the pharmaceutically acceptable salt or glycoside thereof can be used for preparing drugs for treatment or adjuvant treatment or prognosis improvement or prevention of diseases related to imbalance of the antioxidant stress system. # imgabs0 #

The present invention relates to a powder for an edaravone oral suspension dosage form. The invention also relates to providing patient compliant, economical and technically advanced dosage forms over existing dosage forms. In addition, compared with the prior art, the patient compliance edaravone preparation prepared according to the invention is proved to be higher in solubility and stability. In addition, the present invention also provides a powder composition for oral suspension prepared by an improved method that is relatively simple, easy for commercial production, and replicable in function.

The invention provides multifunctional hydrogel carrying neural stem cells. The multifunctional hydrogel mainly comprises the following components: chitosan, beta-sodium glycerophosphate, edaravone, nerve growth factors and the neural stem cells, the invention also provides a method for preparing the multifunctional hydrogel, which comprises the following steps: preparing temperature-sensitive hydrogel by taking a chitosan solution and a beta-sodium glycerophosphate solution as matrixes, preparing an edaravone-nerve growth factor mixed solution, and preparing the edaravone-nerve growth factor composite hydrogel. Sequentially adding a neural stem cell suspension and the mixed solution into a hydrogel system to obtain the multifunctional hydrogel carrying the neural stem cells. The multifunctional hydrogel disclosed by the invention realizes high-efficiency integration of three core functions of temperature-sensitive positioning, drug sustained-release microenvironment regulation and control and cell proliferation and differentiation support, and can remarkably promote spinal cord injury repair.

The invention relates to a solid water-dispersible pharmaceutical composition for use in the treatment of a disease, said treatment comprising dispersing said pharmaceutical composition into an aqueous liquid to produce an enteraliy administrable liquid containing at least 0.5 gram of said pharmaceutical composition and at least 0.3 g / 1 of edaravone, followed by enteral administration of said enteraliy administrable liquid to a human patient in an amount to provide a dose of 30-300 mg of edaravone, said pharmaceutical composition comprising: 2-50 weight % of 3-methyl-l-phenyl-2-pyrazolin-5-one (edaravone); and 3-50 weight % of a water-soluble alkalizing agent. This solid composition containing edaravone can be easily dispersed in an aqueous liquid to prepare an aqueous solution of edaravone that can be ingested by a patient. The solid composition of the invention provides the advantage that when the composition is introduced into water the edaravone dissolves very rapidly and the enteraliy administrable liquid thus obtained has a high oral bioavailability.

The present invention relates to liquid pharmaceutical compositions of edaravone. More specifically, stable solutions of edaravone for enteral administration are provided, wherein the composition is stable for extended period of time. The present invention further relates to stable solutions of edaravone, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by edaravone.

A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.